<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15918084</identifier>
<setSpec>1139-9287</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ros Montalbán, S</dc:author>
<dc:author>Garcia-Garcia, M</dc:author>
<dc:author>Mora Ripoll, R</dc:author>
<dc:description xml:lang="en">INTRODUCTION This study aimed to assess the utility of venlafaxine for the current challenges of treatment of depression (remission and response) in real-world clinical practice. METHOD Observational, prospective, multicenter, cross-national, sixteen-week treatment study including out-patients seen in psychiatry with mild to moderate depressive (HAM-D&lt;or=29) and anxiety symptoms (HAM-A&gt;7) to whom venlafaxine extended release (XR) was prescribed in real-world clinical practice. Remission of symptoms (HAM-D17&lt;or=7 and HAM-A&lt;or=5) was assessed in 2,071 (ITT analysis) and 1,500 patients (per protocol analysis). RESULTS At 4 months of treatment, ITT remission rate after treatment with venlafaxine XR was 66.3 % (1,372/ 2,070) for depression symptoms and 57 % (1,180/2,071) for anxiety symptoms, whereas PP remission rate was 76.1% and 66%, respectively (median dose of venlafaxine XR: 150 mg/day). Of the total number of patients, 19.2% abandoned the study, but only 4.1 % withdrew due to adverse events, the most common of them being nausea (3.87%), headache (2.18%) and constipation (2.06%). CONCLUSIONS Venlafaxine XR showed a high remission rate of either depressive or anxiety symptoms in out-patients with depression, as well as a good tolerability profile, in real-world clinical practice.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2005 May-Jun </dc:date>
<dc:title xml:lang="es">Retos actuales del tratamiento de la depresión: venlafaxina retard y datos de remisión en la práctica clínica habitual.</dc:title>
<dc:title xml:lang="en">[The current challenges of the treatment of depression: venlafaxina extended release and remission outcomes in real-world clinical practice].</dc:title>
<dc:publisher>Actas espanolas de psiquiatria</dc:publisher>
</metadata>
</record>
</pubmed-document>
